Companies / Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc.
Nasdaq: NMRACIK 1885522WATERTOWN, MA
Financials
Ownership
185.3M shares outstanding · as of May 1, 2026
Ownership
| Insiders | 4.08% | 7,556,772 |
| Institutions | 40.82% | 75,633,047 |
| Public float | 55.10% | 102,094,425 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 6
View all →| Insider | % of shares | Shares |
|---|---|---|
Berns Paul LSee Remarks · Director | 3.99% | 7,395,185 |
Aurora Daljit SinghSee Remarks | 0.04% | 82,770 |
Pinto JoshuaPresident | 0.03% | 57,783 |
Milligan Michael LeeSee Remarks | 0.01% | 21,034 |
Duncan JasonSee Remarks | — | — |
Fust Matthew KDirector | — | — |
Institutional holders 109
View all →| Holder | Value | % of shares |
|---|---|---|
| $13.25M | 4.21% | |
| $11.88M | 3.29% | |
| $11.26M | 3.39% | |
| $9.95M | 2.75% | |
| $8.13M | 2.45% | |
| $7.98M | 2.41% | |
| $6.58M | 1.98% | |
| $6.45M | 1.79% | |
| $6.26M | 1.89% | |
| $5.37M | 1.49% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | New | Common Stock | $9.95M | +5.1M | 5,104,097 2.75% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $9.80M | +5.8M +284.79% | 7,791,869 4.21% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $2.03M | +1.2M +306.80% | 1,582,119 0.85% of shares | low |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | New | Common Stock | $1.95M | +1.0M | 1,000,000 0.54% of shares | low |
| Q1 2026 as of | Millennium Management LLC 13F manager | Trim | Common Stock | $-1.68M | -862K -23.83% | 2,754,854 1.49% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | Common Stock | $1.42M | +729K +55.75% | 2,036,692 1.10% of shares | low |
| Q3 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $1.33M | +101K +352.86% | 129,210 0.07% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common Stock | $1.19M | +612K +104.76% | 1,195,310 0.65% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| K2 HealthVentures Equity Trust LLC | Passive13G/A | — |
| Invus, L.P. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| NMRA | Common Stock | 640979100 |